Ray, Emma
Culliford, David http://orcid.org/0000-0003-1663-0253
Kruk, Helen
Gillett, Kate
North, Mal
Astles, Carla M.
Hicks, Alexander
Johnson, Matthew http://orcid.org/0000-0001-5597-6615
Lin, Sharon Xiaowen
Orlando, Rosanna
Thomas, Mike http://orcid.org/0000-0001-5939-1155
Jordan, Rachel E.
Price, David http://orcid.org/0000-0002-9728-9992
Konstantin, Mita
Wilkinson, Tom M. A. http://orcid.org/0000-0003-1771-3851
Article History
Received: 1 June 2020
Accepted: 6 January 2021
First Online: 11 February 2021
Competing interests
: C.M.A. reports receiving speaker’s honoraria from Chiesi, Pfizer, GSK, Teva UK and Orion UK. M.T. reports that neither he nor any member of his close family has any shares in pharmaceutical companies. In the past 3 years, he has received speaker’s honoraria for speaking at sponsored meetings or satellite symposia at conferences from the following companies marketing respiratory and allergy products: GSK, Novartis. He has received honoraria for attending advisory panels with Boehringer Ingelheim, GSK, Novartis. R.E.J. reports that she has received grants from the NIHR, and she is on the primary care advisory board for Boehringer Ingelheim. D.P. reports board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. T.M.A.W. reports personal fees and other from MyMHealth, grants from Innovate UK, grants from GSK, grants and personal fees from AstraZeneca, grants and personal fees from Synairgen and personal fees from BI, outside the submitted work. E.R., D.C., H.K., K.G., M.N., A.H., S.X.L., M.J., R.O. and M.K. report no competing interests.